Genetics and a dig at rivals for the holidays

Share this article:

23andMe's crisis is DNA Spectrum's gain. The rival genetic testing service released an announcement Tuesday, saying that while 23andMe has angered the FDA by promoting product claims it cannot support, the Phoenix, AZ, company “continues to be committed to the protection of consumers in genetic testing.”

DNA Spectrum's announcement notes the company has a “cutting-edge lineup of genetic ancestry services,” and that it is ready to provide “the best personal genetics holiday gifts to share with family and friends.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.